MARKET

VALN

VALN

Valneva Se
NASDAQ
5.66
-0.10
-1.74%
After Hours: 5.66 0 0.00% 16:10 11/13 EST
OPEN
5.88
PREV CLOSE
5.76
HIGH
5.88
LOW
5.66
VOLUME
2.72K
TURNOVER
--
52 WEEK HIGH
12.18
52 WEEK LOW
4.750
MARKET CAP
536.70M
P/E (TTM)
-2.7977
1D
5D
1M
3M
1Y
5Y
1D
Valneva Reports Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate
TipRanks · 8h ago
Valneva Reports Five-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ
NASDAQ · 3d ago
Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups
Benzinga · 3d ago
Valneva Evaluates Next Steps for Bacterial Infection Vaccine Following Successful Phase 2 Studies
Benzinga · 4d ago
Valneva’s Lyme Vaccine Catalysts Support Buy Rating and Significant Upside
TipRanks · 4d ago
Weekly Report: what happened at VALN last week (1102-1106)?
Weekly Report · 4d ago
Valneva Reports Positive Mid-Stage Results For Shigella Vaccine Candidate S4V2
NASDAQ · 4d ago
Valneva Announces November 24 Release of Nine-Month 2026 Results
TipRanks · 11/06 15:27
More
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Webull offers Valneva SE (ADR) stock information, including NASDAQ: VALN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VALN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VALN stock methods without spending real money on the virtual paper trading platform.